유투바이오
Financials
Valuation Metrics
유투바이오's Market Cap is ₩656B. At end of 2025 it was ₩640B. Ranked #1516 of 2,436 in KR market (top 62%), #873 of 1,649 on KOSDAQ (top 53%), #57 of 96 in Health Care Equipment & Services (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 65.60B KRW | KR#1,516/2,436 Sec#57/96 |
| Revenue | 26.95B KRW | KR#2,064/2,436 Sec#67/96 |
| Net Income | -1.79B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 66.58B KRW | KR#2,018/2,436 Sec#64/96 |
| Net Assets | 53.81B KRW | KR#1,822/2,436 Sec#56/96 |
| Employees | 101 | KR#1,615/2,436 Sec#57/96 |
| Value | ||
| P/B | 1.22x | KR#1,687/2,436 Sec#51/96 |
| P/S | 2.43x | KR#1,947/2,436 Sec#60/96 |
| FCF Yield | -2.52% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -3.33% | KR#1,683/2,436 Sec#57/96 |
| ROA | -2.69% | KR#1,748/2,436 Sec#57/96 |
| Op. Margin | -12.03% | KR#2,024/2,436 Sec#68/96 |
| Revenue Growth | 24.16% | KR#569/2,436 Sec#25/96 |
| Financial Health | ||
| Debt Ratio | 123.73% | KR#743/2,436 Sec#35/96 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/96 |
| FCF | -1.65B KRW | KR#1,317/2,436 Sec#39/96 |
| Cash | 16.79B KRW | KR#1,354/2,436 Sec#40/96 |
| Current Ratio | 4.02x | KR#413/2,436 Sec#26/96 |
| Dividend | ||
| Div. Yield | 2.47% | KR#777/2,436 Sec#15/96 |
| Div. Growth | -83.24% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | 32.67% | KR#291/2,436 Sec#5/96 |
| 1M Return | -28.98% | KR#2,304/2,436 Sec#91/96 |
| From 52W High | -87.74% | KR#2,417/2,436 Sec#96/96 |
| 1Y MDD | -87.16% | KR#2,398/2,436 Sec#96/96 |
| Trading | ||
| Volume | 33,610 shares | KR#1,302/2,436 Sec#54/96 |
| Foreign Own. | 0.48% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -133 KRW | KR—/2,436 Sec—/96 |
| BPS | 3,332 KRW | KR#1,740/2,436 Sec#48/96 |
Company Info
Established in 2009, this company was listed on the KONEX market in 2015 and transferred to the KOSDAQ market in 2023. It operates in vitro diagnostic testing services and medical IT solutions, collecting specimens from hospitals and clinics nationwide through directly managed stores and agencies, and delivering analysis results via partner medical institutions. The company is pursuing pharmaceutical clinical services with partner medical institutions and U2Biome, an NGS-based personalized health management solution, as new growth engines. U2Bio was established in 2009 and is headquartered in Songpa-gu, Seoul Metropolitan City.